ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced it has entered into definitive agreements to sell 6,072,383 shares of its common stock at a price per share of $0.8234 pursuant to a registered direct offering to institutional investors, resulting in gross proceeds of approximately $5 million.
